|
|
 |
|
Research
Group
August 2019
(top row, left
to
right) Chester Jar, Maximilian
Aisenstat, Mellissa Gomez, Reinhard Vehring, David
Barona, Hui Wang;
(bottom row, left to right)
Zheng
Wang, Mani
Ordoubadi, Nicholas Carrigy, Shabab Bin Karim.
Principal Investigator
 Dr.
Reinhard
Vehring
particle.engineering@ualberta.ca
Dr.
Vehring is a Professor in the Mechanical Engineering Department at the
University of Alberta and holds the George Ford Chair in Materials
Engineering. He graduated with a diploma in Mechanical Engineering from
the Gerhard Merkator University in Duisburg, Germany, and received a
doctorate from the University of Bochum in the field of molecular
spectroscopy on microparticles. Dr. Vehring has held positions in
academia and industry advancing aerosol science and particle technology
for more than 26 years. Before returning to academia, he worked on
pulmonary delivery of peptides, proteins, and small molecules at Nektar
Therapeutics and was part of the team developing Exubera, the first
inhalable insulin. Subsequently, he developed solid dosage forms for
virus vaccines, monoclonal antibodies, and oncology therapeutics at
Medimmune, and supported FluMist, the first nasally administered live
attenuated influenza vaccine. Dr. Vehring was the lead inventor for the
cosuspension formulation technology which is used by Pearl Therapeutics
to develop metered dose inhaler based therapeutics for respiratory
diseases. At the University of Alberta, Dr. Vehring directs the
Particle Engineering facility focusing on advanced micro and
nanoparticle design and analysis.
Contact Prof.
Vehring
Project Manager & Research Associate
Research Associates
| Hui
Wang |
| Shital
Bachchhav |
Mellissa Gomez
|
| Isobel Tetreau |
Graduate Students
Previous Members:
Students, Postdocs and Research Associates
|
Administrative
Assistant
|
|
|
